Evaluating Treatment Resistant Dermatitis TaroIIR
NCT03050294
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
24
Enrollment
OTHER
Sponsor class
Conditions
Atopic Dermatitis
Psoriasis
Interventions
BEHAVIORAL:
Phone calls
DRUG:
Desoximetasone 0.25% spray
Sponsor
Wake Forest University Health Sciences